Arihant College of Pharmacy, Ahmednagar
Biologics, such as monoclonal antibodies, fusion proteins or recombinant cytokines, have changed the landscape in the treatment of many diseases. On the other hand, due to their large molecule size, advanced structure, and being native like endogeneous substances, the pharmacokinetics (PK) and pharmacodynamics (PD) of these drugs are fundamentally different from those of small molecule drugs. PD of biologics are generally target driven; however, they are closely related to its PK through TMDD and immunogenicity. This review highlights that the intricate relationship of the biologic structure, its target and the patients’ immune system determines the clinical exposure, efficacy and safety of a therapeutic. Appreciation for these distinct ADME characteristics is vital for rational design, preclinical development, and clinical dosing of biologic therapeutics.
Biologics are a diverse class of therapeutic agents derived from living organisms, including monoclonal antibodies, fusion proteins, gene therapy, and vaccines.
The pharmacokinetics (PK) and pharmacodynamics (PD) of biologics differ significantly from small molecules due to their size, complexity, and biological origin.
This study aims to analyse the ADME characteristics of biologics and their impact on pharmacodynamics and therapeutic outcomes.
2. Pharmacokinetics of biologics:
2.1 Absorption
Biologics are administered primarily via intravenous (IV), subcutaneous (SC), and intramuscular (IM) routes.
Unlike small molecules, which are absorbed through passive diffusion, biologics are absorbed via lymphatic transport.
Absorption rates influence the onset of action, with IV administration offering immediate effects.
ROOTS OF ADMINISTRATION :
Many drugs can be administered orally as liquids, capsules, tablets, or chewable tablets. Because the oral route is the most convenient and usually the safest and least expensive, it is the one most often used. However, it has limitations because of the way a drug typically moves through the digestive tract. For drugs administered orally, absorption may begin in the mouth and stomach. However, most drugs are usually absorbed from the small intestine. The drug passes through the intestinal wall and travels to the liver before being transported via the bloodstream to its target site. The intestinal wall and liver chemically alter (metabolize) many drugs, decreasing the amount of drug reaching the bloodstream. Consequently, these drugs are often given in smaller doses when injected intravenously to produce the same effect.
When a drug is taken orally, food and other drugs in the digestive tract may affect how much of and how fast the drug is absorbed. Thus, some drugs should be taken on an empty stomach, others should be taken with food, others should not be taken with certain other drugs or certain foods, and still others cannot be taken orally at all.
Some drugs that are taken orally irritate the digestive tract. For example, aspirin and most other nonsteroidal anti-inflammatory drugs (NSAIDs) can harm the lining of the stomach and small intestine to potentially cause or aggravate pre-existing ulcers. Other drugs are absorbed poorly or erratically in the digestive tract or are destroyed by the acid and digestive enzymes in the stomach.
Other routes of administration are required when the oral route cannot be used, for example:
2) INJECTION ROUTES :
Administration by injection (parenteral administration) includes the following routes:
A drug product can be prepared or manufactured in ways that prolong drug absorption from the injection site for hours, days, or longer. Such products do not need to be administered as often as drug products with more rapid absorption.
For the subcutaneous route, a needle is inserted into fatty tissue just beneath the skin. After a drug is injected, it then moves into small blood vessels (capillaries) and is carried away by the bloodstream. Alternatively, a drug reaches the bloodstream through the lymphatic vessels (see figure Lymphatic System: Helping Defend Against Infection). Protein drugs that are large in size, such as insulin, usually reach the bloodstream through the lymphatic vessels because these drugs move slowly from the tissues into capillaries. The subcutaneous route is used for many protein drugs because such drugs would be destroyed in the digestive tract if they were taken orally.
Certain drugs (such as progestin’s used for hormonal birth control) may be given by inserting plastic capsules under the skin (implantation). This route of administration has the main advantage of providing a long-term therapeutic effect (for example, etonogestrel that is implanted for contraception may last up to 3 years).
The intramuscular route is preferred to the subcutaneous route when larger volumes of a drug product are needed. Because the muscles lie below the skin and fatty tissues, a longer needle is used. Drugs are usually injected into the muscle of the upper arm, thigh, or buttock. How quickly the drug is absorbed into the bloodstream depends, in part, on the blood supply to the muscle: The sparser the blood supply, the longer it takes for the drug to be absorbed.
For the intravenous route, a needle is inserted directly into a vein. A solution containing the drug may be given in a single dose or by continuous infusion. For infusion, the solution is moved by gravity (from a collapsible plastic bag) or, more commonly, by an infusion pump through thin flexible tubing to a tube (catheter) inserted in a vein, usually in the forearm. Intravenous administration is the best way to deliver a precise dose quickly and in a well-controlled manner throughout the body. It is also used for irritating solutions, which would cause pain and damage tissues if given by subcutaneous or intramuscular injection. An intravenous injection can be more difficult to administer than a subcutaneous or intramuscular injection because inserting a needle or catheter into a vein may be difficult, especially if the person has obesity.
When given intravenously, a drug is delivered immediately to the bloodstream and tends to take effect more quickly than when given by any other route. Consequently, health care professionals closely monitor people who receive an intravenous injection for signs that the drug is working or is causing undesired side effects. Also, the effect of a drug given by this route tends to last for a shorter time. Therefore, some drugs must be given by continuous infusion to keep their effect constant.
For the intrathecal route, a needle is inserted between two vertebrae in the lower spine and into the space around the spinal cord. The drug is then injected into the spinal canal. A small amount of local anesthetic is often used to numb the injection site. This route is used when a drug is needed to produce rapid or local effects on the brain, spinal cord, or the layers of tissue covering them (meninges)—for example, to treat infections of these structures. Anesthetics and analgesics (such as morphine) are sometimes given this way.
3) SUBLINGUAL AND BUCCAL ROUTES
A few drugs are placed under the tongue (taken sublingually) or between the gums and teeth (buccally) so that they can dissolve and be absorbed directly into the small blood vessels that lie beneath the tongue. These drugs are not swallowed. The sublingual route is especially good for nitroglycerin, which is used to relieve angina, because absorption is rapid and the drug immediately enters the bloodstream without first passing through the intestinal wall and liver. However, most drugs cannot be taken this way because they may be absorbed incompletely or erratically.
4) RECTAL ROUTE
Many drugs that are administered orally can also be administered rectally as a suppository. In this form, a drug is mixed with a waxy substance that dissolves or liquefies after it is inserted into the rectum. Because the rectum’s wall is thin and its blood supply rich, the drug is readily absorbed. A suppository is prescribed for people who cannot take a drug orally because they have nausea, cannot swallow, or have restrictions on eating, as is required before and after many surgical operations. Drugs that can be administered rectally include acetaminophen (for fever), diazepam (for seizures), and laxatives (for constipation). Drugs that are irritating in suppository form may have to be given by injection.
5) INHALATION ROUTE
Drugs administered by inhalation through the mouth must be atomized into smaller droplets than those administered by the nasal route, so that the drugs can pass through the windpipe (trachea) and into the lungs. How deeply into the lungs they go depends on the size of the droplets. Smaller droplets go deeper, which increases the amount of drug absorbed. Inside the lungs, they are absorbed into the bloodstream.
Relatively few drugs are administered this way because inhalation must be carefully monitored to ensure that a person receives the right amount of drug within a specified time. In addition, specialized equipment may be needed to give the drug by this route. Usually, this method is used to administer drugs that act specifically on the lungs, such as aerosolized antiasthmatic drugs in metered-dose containers (called inhalers), and to administer gases used for general anaesthesia.
6) TRANSDERMAL ROUTE
Some drugs are delivered bodywide through a patch on the skin. These drugs are sometimes mixed with a chemical (such as alcohol) that enhances penetration through the skin into the bloodstream without any injection. Through a patch, the drug can be delivered slowly and continuously for many hours or days or even longer. As a result, levels of a drug in the blood can be kept relatively constant. Patches are particularly useful for drugs that are quickly eliminated from the body because such drugs, if taken in other forms, would have to be taken frequently. However, patches may irritate the skin of some people. In addition, patches are limited by how quickly the drug can penetrate the skin. Only drugs to be given in relatively small daily doses can be given through patches. Examples of such drugs include nitroglycerin (for chest pain), scopolamine (for motion sickness), nicotine (for smoking cessation), clonidine (for high blood pressure), and fentanyl (for pain relief).
Difference in bioavailability across routes
Bioavailability refers to the extent and rate at which the active moiety (drug or metabolite) enters the systemic circulation, thereby accessing the site of action.
Bioavailability of a drug is largely determined by the properties of the dosage form, which depend partly on its design and manufacture. Differences in bioavailability among formulations of a given drug can have clinical significance; thus, knowing whether drug formulations are equivalent is essential.
Chemical equivalence indicates that drug products contain the same active compound in the same amount and meet current official standards; however, inactive ingredients in drug products may differ. Bioequivalence indicates that the drug products, when given to the same patient in the same dosage regimen, result in equivalent concentrations of drug in plasma and tissues. Therapeutic equivalence indicates that drug products, when given to the same patient in the same dosage regimen, have the same therapeutic and adverse effects.
Bioequivalent products are expected to be therapeutically equivalent. Therapeutic non-equivalence (e.g., more adverse effects, less efficacy) is usually discovered during long-term treatment when patients who are stabilized on one formulation are given a non-equivalent substitute.
Sometimes therapeutic equivalence is possible despite differences in bioavailability. For example, the therapeutic index (ratio of the minimum toxic concentration to the median effective concentration) of penicillin is so wide that efficacy and safety are usually not affected by the moderate differences in plasma concentration due to bioavailability differences in penicillin products. In contrast, for drugs with a relatively narrow therapeutic index, bioavailability differences may cause substantial therapeutic non-equivalence.
CAUSE OF LOW BIOAVAILABILITY
Orally administered drugs must pass through the intestinal wall and then the portal circulation to the liver; both are common sites of first-pass metabolism (metabolism that occurs before a drug reaches systemic circulation). Thus, many drugs may be metabolized before adequate plasma concentrations are reached. Low bioavailability is most common with oral dosage forms of poorly water-soluble, slowly absorbed drugs.
Insufficient time for absorption in the gastrointestinal (GI) tract is a common cause of low bioavailability. If the drug does not dissolve readily or cannot penetrate the epithelial membrane (e.g., if it is highly ionized and polar), time at the absorption site may be insufficient. In such cases, bioavailability tends to be highly variable as well as low.
Age, sex, physical activity, genetic phenotype, stress, disorders (e.g., achlorhydria, malabsorption syndromes), or previous GI surgery (e.g., bariatric surgery) can also affect drug bioavailability.
Chemical reactions that reduce absorption can decrease bioavailability. They include formation of a complex (e.g., between tetracycline and polyvalent metal ions), hydrolysis by gastric acid or digestive enzymes (eg, penicillin and chloramphenicol palmitate hydrolysis), conjugation in the intestinal wall (e.g., sulfoconjugation of isoproterenol), adsorption to other drugs (e.g., digoxin to cholestyramine), and metabolism by luminal microflora.
ASSESSING BIOAVAILABILITY
Bioavailability is usually assessed by determining the area under the plasma concentration–time curve (AUC—see figure Representative Plasma Concentration–Time Relationship After a Single Oar...). The most reliable measure of a drug’s bioavailability is AUC. AUC is directly proportional to the total amount of unchanged drug that reaches systemic circulation. Drug products may be considered bioequivalent in extent and rate of absorption if their plasma concentration curves are essentially superimposable.
Representative Plasma Concentration–Time Relationship After a Single Oral Dose of a Hypothetical Drug.
Plasma drug concentration increases with extent of absorption; the maximum (peak) plasma concentration is reached when drug elimination rate equals absorption rate. Bioavailability determinations based on the peak plasma concentration can be misleading because drug elimination begins as soon as the drug enters the bloodstream. Peak time (when maximum plasma drug concentration occurs) is the most widely used general index of absorption rate; the slower the absorption, the later the peak time.
For drugs excreted primarily unchanged in urine, bioavailability can be estimated by measuring the total amount of drug excreted after a single dose. Ideally, urine is collected over a period of 7 to 10 elimination half-lives for complete urinary recovery of the absorbed drug. After multiple dosing, bioavailability may be estimated by measuring unchanged drug recovered from urine over a 24-hour period under steady-state conditions.
2.2 Distribution
When a drug is absorbed and enters the systemic circulation, it is naturally distributed throughout the fluid and tissues in the body. Drug distribution is a subject that is covered in a branch of pharmacology called pharmacokinetics.
The drug distribution is usually varied, and depends on several factors such as:
Additionally, the rate at which a drug enters into a tissue depends on:
The drug will eventually reach a distribution equilibrium, when the rate of drug entry and exit between the blood and the tissue is equal. At this point, when equilibrium has been reached, the concentration of the drug in the tissues and extracellular fluids is reflected by the concentration of the drug in the blood plasma. However, drug distribution is a dynamic process, because it occurs simultaneously with other pharmacokinetic processes such as drug metabolism and excretion.
PLASMA PROTEIN BINDING
The distribution of a drug in the body also depends on the extent to which the drug binds to proteins and tissues in the body. Only drugs that are unbound to proteins and other components in the blood are free to diffuse across the cell membranes into the tissues of the body.
The most important proteins in the blood that can affect the distribution of a drug include the plasma protein albumin, the alpha-1 acid glycoprotein, and lipoproteins. It is observed that albumin binds acidic drugs, in general, while more basic drugs bind to the lipoproteins and acid glycoprotein. Although proteins are the most common binding sites in the blood, there are other molecules in the blood to which a drug molecule may bind.
As only the unbound drug can be utilized in extravascular and tissue sites, it is important to establish or estimate the unbound drug fraction in the blood. The following equation is used for this:
Unbound fraction = unbound drug concentration in plasma / total drug concentration in plasma
When there is a high concentration of drug in the body, there is an upper limit that is reached with respect to the total amount of drug that can be bound to proteins. This is based on the number of saturable binding sites.
Pharmaceutical substances can accumulate in tissues of the body. They may then be slowly released into the circulation as the blood concentration of the drug decreases, leading to a prolongation of drug action. Some drugs may show a similar accumulation within the body cells, being bound to intracellular proteins, phospholipids or even the DNA or RNA.
Volume of Distribution (Vd)
The apparent volume of distribution (VD) is the volume of fluid in which the total drug dose would theoretically have to be diluted to produce the observed drug concentration in the blood plasma. It can be calculated as follows:
Apparent volume of distribution = amount of drug in body / drug concentration in plasma
It is a theoretical value that is not related to the actual body volume of the individual, but is a useful pharmacokinetic parameter that indicates the distribution of the drug in the body.
For example, a drug that easily distributes into the tissues of the body will have a lower concentration in the blood, and the VD will be high as a result. Conversely, drugs that tend to remain in the blood and do not distribute easily to the tissue will have a higher concentration in the blood and a lower VD.
Tissue Penetration and Bio-distribution
Biologics face challenges in crossing biological barriers, including the blood-brain barrier (BBB). Due to their large molecular size and hydrophilic nature, most biologics cannot freely diffuse across endothelial barriers. Instead, receptor-mediated transport mechanisms, such as FcRn-mediated recycling and endocytosis, play a crucial role in their bio-distribution. In the central nervous system (CNS), transport of biologics across the BBB is highly restricted, limiting their therapeutic applications for neurological diseases. Some strategies, such as antibody engineering for BBB penetration or utilizing carrier systems, are being explored to enhance CNS delivery.
Factors Influencing Distribution
Molecular weight, receptor binding affinity, and FcRn-mediated recycling impact the distribution profile of biologics. High molecular weight reduces tissue penetration, confining biologics to the vascular and extracellular compartments. Receptor binding affinity influences target-mediated drug disposition (TMDD), where biologics may be internalized and degraded within cells upon binding to their target receptors. FcRn-mediated recycling extends the half-life of IgG-based biologics by preventing their lysosomal degradation, allowing them to be re-released into circulation, thereby improving their bioavailability and therapeutic duration.
2.3 METABOLISM
Cytochrome P450 (CYP450) enzymes are responsible for the biotransformation or metabolism of about 70-80% of all drugs in clinical use.
What are some factors that affect drug metabolism?
Genetics can impact whether someone metabolizes drugs more quickly or slowly.
Age can impact liver function; the elderly have reduced liver function and may metabolize drugs more slowly, increasing risk of intolerability, and new-born’s or infants have immature liver function and may require special dosing considerations.
Drug interactions can lead to decreased drug metabolism by enzyme inhibition or increased drug metabolism by enzyme induction.
Generally, when a drug is metabolized through CYP450 enzymes, it results in inactive metabolites, which have none of the original drug’s pharmacologic activity. However, certain medications, like codeine, are inactive and become converted in the body into a pharmacologically active drug. These are commonly referred to as prodrugs.
As you can imagine, having genetic variations in CYP2D6, the metabolic pathway for codeine, can have significant clinical consequences. Usually, CYP2D6 poor metabolizers (PMs) have higher serum levels of active drugs. In codeine, PMs have higher serum levels of the inactive drug, which could result in inefficacy. Conversely, ultra-rapid metabolizers (UMs) will transform codeine to morphine extremely quickly, resulting in toxic morphine levels.
The FDA added a black box warning to the codeine drug label, stating that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who have evidence of being a CYP2D6 UM.
PROTEOLYTIC DEGRADATION
Biologics, including monoclonal antibodies, peptides, and fusion proteins, are primarily metabolized by proteolytic enzymes in lysosomes and extracellular spaces. This differs from the metabolism of small-molecule drugs, which largely rely on cytochrome P450 (CYP) enzymes in the liver. Once internalized, biologics are broken down into smaller peptides and amino acids, which are subsequently recycled or eliminated. This process reduces the risk of hepatotoxicity and bypasses CYP-related drug-drug interactions, making biologics a preferable option in polypharmacy settings.
RECEPTOR-MEDIATED CLEARANCE
Target-mediated drug disposition (TMDD) plays a significant role in the clearance of biologics. Biologics often bind to specific target receptors, leading to receptor-mediated endocytosis. This internalization process results in the degradation of the drug within lysosomes. The extent of TMDD depends on the receptor expression levels, drug affinity, and availability of soluble receptors. In cases of high-affinity binding and receptor saturation, nonlinear pharmacokinetics can be observed, complicating dose optimization and therapeutic monitoring. Additionally, Fc receptor (FcRn)-mediated recycling can extend the half-life of monoclonal antibodies and Fc-fusion proteins, delaying their clearance.
METABOLISM PATHWAYS
Unlike small molecules, biologics undergo metabolism through non-CYP pathways, reducing the risk of drug-drug interactions commonly seen with CYP enzymes. Their degradation primarily involves proteolysis in the reticuloendothelial system (RES), kidneys, and target tissues. Factors such as glycosylation, PEGylation, and structural modifications influence their stability, bioavailability, and clearance. Some biologics, particularly antibody-drug conjugates (ADCs), have complex metabolic profiles due to the presence of both biologic and small-molecule components, requiring specialized strategies to predict their pharmacokinetics and optimize therapeutic efficacy.
The clearance mechanisms of biologics are highly dependent on molecular characteristics, receptor interactions, and tissue distribution, necessitating a comprehensive understanding of their pharmacokinetics for effective drug development and therapeutic use.
2.4 EXCRETION
Excretion
Excretion is the final stage of a medication interaction within the body. The body has absorbed, distributed, and metabolized the medication molecules – now what does it do with the leftovers? Remaining parent drugs and metabolites in the bloodstream are often filtered by the kidney, where a portion undergoes reabsorption back into the bloodstream, and the remainder is excreted in the urine. The liver also excretes by-products and waste into the bile. Another potential route of excretion is the lungs. For example, drugs like alcohol and the anesthetic gases are often eliminated by the lungs.
ROUTES OF EXCRETION
KIDNEY
The most common route of excretion is through the kidneys. As the kidneys filter blood, the majority of drug by-products and waste are excreted in the urine. The rate of excretion can be estimated by taking into consideration several client factors, including age, weight, biological sex, and kidney function. There are known sex differences in the three main renal functions of glomerular filtration, tubular secretion and tubular reabsorption. Renal clearance is generally higher in men than in women.
Kidney function is measured by lab values such as serum creatinine, glomerular filtration rate (GFR), and creatinine clearance. If a client’s kidney function is decreased, then their ability to excrete medication is affected, and drug dosages must be altered for safe administration.
Renal disorders, such as chronic kidney disease, can reduce kidney function and hinder drug excretion. As kidney function decreases with age, drug excretion becomes less efficient, and dosing adjustments may be needed. Other medical conditions that impact blood flow to the kidneys can also affect drug elimination. For example, heart failure can affect systemic blood flow to the kidney, resulting in decreased filtration and elimination of drugs.
LIVER
As the liver filters blood, some drugs and their metabolites are actively transported by hepatocytes (liver cells) to bile. Bile moves through the bile ducts to the gallbladder and then on to the small intestine. During this process, some drugs may be partially absorbed by the intestine back into the bloodstream. Other drugs are biotransformed (metabolized) by intestinal bacteria and reabsorbed. Unabsorbed drugs and by-products/metabolites are excreted in the faces.
If a client has decreased liver function, their ability to excrete medication is affected, and drug dosages must be adjusted. Lab studies used to evaluate liver function are called liver function tests and include measurement of alanine transaminase (ALT) and aspartate aminotransferase (AST) enzymes that the body releases in response to damage to or disease of the liver.
Conditions that cause decreased blood flow to the liver can also affect the metabolism and excretion of drugs. For example, conditions such as shock, hypovolemia, or hypotension cause decreased liver perfusion and may require adjustment of dosages of medication.
OTHER ROUTES TO CONSIDER
Sweat, tears, reproductive fluids (such as seminal fluid), and breast milk can also contain drugs and by-products/metabolites of drugs. This can pose a toxic threat, such as the exposure of an infant to breast milk containing drugs or by-products of drugs ingested by the mother. Therefore, nurses must refer to a drug reference and contact a health care provider with any concerns before administering medications to a mother who is breastfeeding.
LIFE SPAN CONSIDERATIONS:-
NEONATE & PEDIATRICS
Neonates and children have immature kidneys with decreased glomerular filtration, resorption, and tubular secretion. As a result, they do not excrete medications as efficiently from the body. Dosing for most medications used to treat infants and pediatric clients is commonly based on weight in kilograms, and a smaller dose is usually prescribed. In addition, pediatric clients may have higher levels of free circulating medication than anticipated and may become toxic quickly. Therefore, it is vital for nurses to diligently recheck dosages before administering medications and closely monitor infants and children for early identification of adverse effects and drug toxicity.
OLDER ADULT
Kidney and liver function often decrease with age, which can lead to decreased metabolism and excretion of medications. Subsequently, medication may have a prolonged half-life with a greater potential for toxicity due to elevated circulating drug levels. Some medications may be avoided or smaller doses recommended for older clients due to these factors, which is commonly referred to as “Start low and go slow.”
3. PHARMACODYNAMICS OF BIOLOGICS:-
3.1 Mechanisms of Action
Target Engagement and Binding Kinetics:
Biologics exert their therapeutic effects by specifically binding to target molecules such as receptors, enzymes, cytokines, or surface proteins. The efficacy of biologics depends on their binding kinetics, including association (on-rate) and dissociation (off-rate) constants, which determine target occupancy and duration of action. Unlike small molecules, which often rely on passive diffusion, biologics typically require receptor-mediated endocytosis or FcRn recycling for sustained activity.
Receptor Down regulation and Signal Modulation:
Certain biologics function by inducing receptor internalization and down regulation, reducing receptor availability on the cell surface. This can lead to signal modulation, altering intracellular pathways involved in disease progression. For instance, monoclonal antibodies targeting tumor necrosis factor-alpha (TNF-α) can block pro-inflammatory signaling, mitigating autoimmune conditions such as rheumatoid arthritis. Additionally, biologics that act as receptor agonists or antagonists can influence cell proliferation, apoptosis, or immune activation, contributing to their therapeutic effects.
3.2 Dose-Response Relationship
Nonlinear PK/PD Profiles:
Biologics frequently exhibit nonlinear pharmacokinetics (PK) and pharmacodynamics (PD) due to target-mediated drug disposition (TMDD). Unlike small molecules, whose clearance is often dose-proportional, biologics experience saturable binding to target receptors, leading to dose-dependent changes in elimination rates. For example, at low doses, receptor binding dominates clearance, whereas at higher doses, non-specific clearance mechanisms become more relevant. This complexity necessitates specialized PK/PD modeling to optimize dosing strategies.
Factors Affecting PD Variability
Several intrinsic and extrinsic factors contribute to PD variability in biologics:
Anti-Drug Antibodies (ADA) and Neutralization
Immunogenicity, the ability of biologics to provoke an immune response, remains a major concern. The formation of anti-drug antibodies (ADAs) can lead to drug neutralization, reducing therapeutic efficacy. ADAs may be:
Impact on Drug Efficacy and Safety:-
Immunogenicity can lead to loss of drug response, hypersensitivity reactions, or cross-reactivity with endogenous proteins. In severe cases, ADA formation necessitates switching to alternative biologics or adjusting dosing regimens. Strategies to mitigate immunogenicity include:
4. Factors Influencing PK/PD of Biologics:-
Patient-Specific Factors
Variability in PK/PD responses among patients is influenced by:
Drug-Drug and Drug-Target Interactions:-
Unlike small molecules, biologics have minimal interactions with CYP enzymes. However, interactions may occur through:
Formulation and Delivery Innovations:-
Advancements in drug delivery aim to improve biologic stability, bioavailability, and patient adherence:
5. Clinical Implications and Therapeutic Considerations
Personalized Dosing Strategies
Due to high interpatient variability, personalized dosing approaches are crucial. Strategies include:
Therapeutic Drug Monitoring (TDM) in Biologics
TDM is gaining traction in biologic therapy to:
Regulatory Considerations for Biologics and Biosimilars
Regulatory agencies, such as the FDA and EMA, have stringent guidelines for:
6. Future Directions and Challenges
Advances in Computational and AI-Based PK/PD Modeling
AI-driven technologies are transforming biologic drug development:
Novel Biologic Therapies and Emerging Trends
The next generation of biologics includes:
Challenges in Translating PK/PD Insights into Clinical Practice
Despite advances, challenges remain:
Biologic therapies continue to transform modern medicine, offering targeted and highly effective treatments. However, optimizing their PK/PD properties, minimizing immunogenicity, and ensuring widespread accessibility remain key challenges for the future.
CONCLUSION
Biologics represent a rapidly evolving class of therapeutics with distinct pharmacokinetic and pharmacodynamic profiles compared to small-molecule drugs. Their absorption, distribution, metabolism, and excretion (ADME) characteristics, along with target-mediated drug disposition (TMDD) and receptor-mediated clearance, necessitate a comprehensive understanding for optimal therapeutic application. The non-linear PK/PD relationships, immunogenicity concerns, and interpatient variability highlight the importance of personalized dosing strategies and therapeutic drug monitoring (TDM). Future research should focus on improving biologic stability, enhancing drug delivery mechanisms, and developing AI-driven predictive models for better PK/PD characterization. Advancements in gene therapy, multi-specific antibodies, and mRNA-based biologics hold promise for treating previously untreatable conditions. Regulatory frameworks for biosimilars continue to evolve, ensuring safety and efficacy while promoting accessibility. Overcoming cost and immunogenicity challenges will be key to making biologic therapies more effective and widely available.
ACKNOWLEDGMENTS
We are thankful to Arihant College of Pharmacy Kedgaon, Ahmednagar. For providing us with the platform and infrastructure for preparing this research also thanks to our principal Dr. Yogesh Bafana sir, and special thanks to Associate Professor Sneha Kanase, Assistant Professor Mr. Swapnil. G. Kale for their support and expert opinion during the writing process.
REFERENCES
Punam Bangar, Sejal Bhandari, Swapnil Kale, Sneha Kanase, Pharmacokinetics and Pharmacodynamics of Biologics: Analyzing the Unique Characteristics of Biologics in Terms of Their Absorption, Distribution, Metabolism, and Excretion, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 802-818. https://doi.org/10.5281/zenodo.17539300
10.5281/zenodo.17539300
